(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.08%) $79.06
(5.02%) $2.03
(0.10%) $2 313.40
(0.68%) $26.93
(0.85%) $963.00
(-0.07%) $0.932
(-0.26%) $11.00
(-0.05%) $0.798
(-2.30%) $91.12
Live Chart Being Loaded With Signals
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures...
Stats | |
---|---|
今日成交量 | 1.30M |
平均成交量 | 954 109 |
市值 | 10.66B |
EPS | $0 ( 2024-02-27 ) |
下一个收益日期 | ( $0 ) 2024-08-01 |
Last Dividend | $0.288 ( 2023-10-05 ) |
Next Dividend | $0 ( N/A ) |
P/E | 40.73 |
ATR14 | $0.0120 (0.05%) |
音量 相关性
Smith & Nephew SNATS Inc. 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Smith & Nephew SNATS Inc. 相关性 - 货币/商品
Smith & Nephew SNATS Inc. 财务报表
Annual | 2023 |
营收: | $5.55B |
毛利润: | $3.70B (66.70 %) |
EPS: | $0.600 |
FY | 2023 |
营收: | $5.55B |
毛利润: | $3.70B (66.70 %) |
EPS: | $0.600 |
FY | 2022 |
营收: | $5.22B |
毛利润: | $3.70B (70.85 %) |
EPS: | $0.510 |
FY | 2021 |
营收: | $5.21B |
毛利润: | $3.67B (70.40 %) |
EPS: | $1.196 |
Financial Reports:
No articles found.
Smith & Nephew SNATS Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.288 (N/A) |
$0 (N/A) |
$0.462 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0.288 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.139 | 2000-05-04 |
Last Dividend | $0.288 | 2023-10-05 |
Next Dividend | $0 | N/A |
Payout Date | 2023-11-01 | |
Next Payout Date | N/A | |
# dividends | 48 | -- |
Total Paid Out | $10.43 | -- |
Avg. Dividend % Per Year | 1.50% | -- |
Score | 4.56 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.94 | |
Div. Directional Score | 8.27 | -- |
Year | Amount | Yield |
---|---|---|
2000 | $0.194 | 2.88% |
2001 | $0.146 | 1.58% |
2002 | $0.154 | 1.28% |
2003 | $0.169 | 1.36% |
2004 | $0.184 | 1.10% |
2005 | $0.194 | 0.96% |
2006 | $0.204 | 1.08% |
2007 | $0.223 | 1.07% |
2008 | $0.247 | 1.07% |
2009 | $0.271 | 2.08% |
2010 | $0.299 | 1.45% |
2011 | $0.328 | 1.56% |
2012 | $0.414 | 2.12% |
2013 | $0.532 | 2.39% |
2014 | $0.560 | 1.98% |
2015 | $0.608 | 1.69% |
2016 | $0.626 | 1.80% |
2017 | $0.616 | 2.05% |
2018 | $0.734 | 2.10% |
2019 | $0.728 | 2.00% |
2020 | $0.750 | 1.55% |
2021 | $0.750 | 1.75% |
2022 | $0.750 | 2.14% |
2023 | $0.750 | 2.75% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
SCM | Dividend King | 2023-12-15 | Monthly | 13 | 7.08% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
SJT | Dividend Royal | 2023-11-29 | Monthly | 39 | 12.52% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
ORC | Dividend Royal | 2023-11-29 | Monthly | 12 | 9.23% | 8.50 |
SRV | Dividend Royal | 2023-12-04 | Monthly | 18 | 7.53% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0475 | 1.500 | 9.05 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0263 | 1.200 | 9.12 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0502 | 1.500 | -0.553 | -0.830 | [0.1 - 1] |
payoutRatioTTM | 1.247 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 1.775 | 0.800 | 6.13 | 4.90 | [1 - 3] |
quickRatioTTM | 0.679 | 0.800 | -0.709 | -0.567 | [0.8 - 2.5] |
cashRatioTTM | 0.133 | 1.500 | -0.372 | -0.558 | [0.2 - 2] |
debtRatioTTM | 0.294 | -1.500 | 5.09 | -7.64 | [0 - 0.6] |
interestCoverageTTM | 5.49 | 1.000 | 9.08 | 9.08 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.384 | 2.00 | 9.54 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.412 | 2.00 | 9.79 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.564 | -1.500 | 7.75 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.688 | 1.000 | 1.862 | 1.862 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.137 | 1.000 | 9.25 | 9.25 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.205 | 1.000 | 9.97 | 9.97 | [0.2 - 2] |
assetTurnoverTTM | 0.553 | 0.800 | 9.64 | 7.72 | [0.5 - 2] |
Total Score | 10.60 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 40.12 | 1.000 | 6.05 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0502 | 2.50 | -0.356 | -0.830 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.412 | 2.00 | 9.86 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.11 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.384 | 2.00 | 9.54 | 10.00 | [0 - 30] |
payoutRatioTTM | 1.247 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 1.550 | 1.500 | 3.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.109 | 1.000 | 9.77 | 0 | [0.1 - 0.5] |
Total Score | 5.94 |
Smith & Nephew SNATS Inc.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。